25 results about "Omeprazole" patented technology

The present application relates to a kind of sulfide monooxygenase mutant and its application in esomeprazole synthesis.The sulfide monooxygenase mutant, its encoding gene, the preparation method of the recombinant expression vector containing the gene sequence, co-expression recombinant vector and recombinant expression transformant, and the application of the recombinant sulfide monooxygenase mutant catalyst in esomeprazole synthesis are specifically disclosed.Compared with other sulfide monooxygenases, the sulfide monooxygenase mutant obtained by the present application can efficiently utilize the coenzyme NADH with lower cost and higher stability to catalyze the asymmetric oxidation reaction of omeprazole sulfide, prepare esomeprazole, has the advantages of high substrate concentration, mild reaction condition, environment-friendly, simple operation, high yield, low production cost and good industrial application prospect.

The invention discloses a traditional Chinese medicine-probiotic combined preparation, a preparation method thereof and application of the traditional Chinese medicine-probiotic combined preparation in gastric mucosal lesion protection. The preparation is composed of a traditional Chinese medicine extract and a bacillus subtilis bacterial suspension, the traditional Chinese medicine extract is prepared from radix codonopsis, rhizoma smilacis glabrae, rhizoma atractylodis macrocephalae, fructus aurantii, radix aucklandiae, bletilla striata, herba ecliptae, radix salviae miltiorrhizae, fructus arctii and fructus psoraleae according to a specific proportion through water decoction, filtration, freeze-drying and mixing with the prepared bacterial suspension. The combined preparation has remarkable protection and treatment effects on gastric mucosal lesion caused by helicobacter pylori infection and ethanol, not only can effectively inhibit the growth of helicobacter pylori, but also can relieve gastric inflammatory response and apoptosis, and the effect of the combined preparation is equivalent to or even better than that of a conventional triple therapy or omeprazole. Meanwhile, the preparation shows synergistic interaction functions of regulating body immunity and maintaining intestinal flora balance, the preparation process is simple and convenient, the safety is high, and the preparation has wide application prospects in preparation of drugs for resisting helicobacter pylori, protecting gastric mucosa and regulating intestinal flora.

The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.

1. The name of the design product: packaging box (omeprazole enteric-coated tablets). 2. The use of the design product: used for the outer packaging of products. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: the unfolded state reference drawing.

The present application discloses a co-crystal of omeprazole and 2,6-dihydroxybenzoic acid, wherein the molar ratio of omeprazole to 2,6-dihydroxybenzoic acid is 1:1, and the co-crystal has higher solubility, dissolution rate, bioavailability and stability compared with omeprazole.

This invention discloses an omeprazole enteric-coated composition, which is prepared by hot melt extrusion of omeprazole, a solid lipid carrier, a surfactant, a pH-sensitive polymer, and a plasticizer to form a biphase matrix structure with the pH-sensitive polymer as the continuous phase and the omeprazole-containing lipid phase as the dispersed phase. The preparation method is also disclosed, thereby achieving gastric protection of omeprazole, rapid intestinal release, and good storage stability.

This invention provides a method for preparing a proton pump inhibitor thioether intermediate. The method involves reacting 3,5-dimethyl-4-methoxy-2-pyridinemethanethiol as a raw material with paraformaldehyde to obtain an intermediate, which is then further reacted with 4-methoxy-o-phenylenediamine, followed by post-treatment to obtain omeprazole thioether. This preparation method is novel, simple to operate, produces a high-purity product, and is suitable for industrial production.

The present application discloses a co-crystal of omeprazole and 3,5-dinitrobenzoic acid, wherein the molar ratio of omeprazole to 3,5-dinitrobenzoic acid is 1:1, and the co-crystal has higher stability, in-vivo absorption speed and onset speed compared with omeprazole.

The invention provides an omeprazole enteric capsule and a preparation method thereof, and belongs to the technical field of medicines. The omeprazole enteric-coated capsule is prepared by taking an omeprazole derivative as an active component and embedding the omeprazole derivative through a sustained-release enteric-coated material. According to the omeprazole enteric capsule prepared by the invention, by adjusting the molecular structure of omeprazole, the water solubility and the bioavailability of omeprazole are improved, the half-life period is prolonged, and by embedding the sustained-release enteric material, the targeted slow release of intestinal tracts is realized, so that the drug effect time is prolonged, the problem of repeated medication is avoided, the compliance of patients is improved, and the bioavailability of the omeprazole enteric capsule is improved. Wide application prospects are realized.

This invention provides a quetiapine fumarate tablet composition and its preparation method. The composition contains the following components: quetiapine fumarate-hydroxypropyl-β-cyclodextrin co-treated product, povidone, calcium hydrogen phosphate, microcrystalline cellulose, sodium carboxymethyl starch, lactose monohydrate, magnesium stearate, and omeprazole. This invention also provides a method for processing a large-particle-size, highly fluid, highly soluble, and stable active pharmaceutical ingredient (API). This involves adding the API to a hydroxypropyl-β-cyclodextrin solution, homogenizing the resulting suspension, and spray-drying to prepare the quetiapine fumarate-hydroxypropyl-β-cyclodextrin co-treated product. The resulting intermediate powder obtained by wet granulation of the above-mentioned API-containing product exhibits superior flowability, smaller relative standard deviation of content uniformity, and a faster tableting rate after compression compared to tablets prepared solely from large-particle-size APIs, which is highly beneficial for industrial-scale production.

To provide a pediatric suspension formulation.SOLUTION: The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.SELECTED DRAWING: None

The present invention relates to a coated tablet composition comprising omeprazole (KN510) with improved stability and a method for preparing the same. More specifically, the present invention relates to a bilayer coated tablet composition comprising omeprazole, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, and a method for preparing the same. In the present invention, in order to increase the stability of a KN510 tablet (30 mg) comprising omeprazole, a tablet composition is designed using calcium carbonate. It is proved that when mannitol and lactose are contained as excipients, tablets satisfying disintegration, dissolution and friability standards can be prepared, and the increase of related substances is significantly reduced.

This invention discloses an esomeprazole sodium and its purification method, relating to the field of drug synthesis technology. The purification method includes the following steps: S1, mechanically grinding crude esomeprazole sodium with a composite solid purification additive to obtain an activated mixture; the composite solid purification additive is a composition of diisopropyl tartrate and hydroxypropyl-β-cyclodextrin, and the mass ratio of diisopropyl tartrate to hydroxypropyl-β-cyclodextrin is (1~5):(2~4); S2, adding a washing solvent to the activated mixture and stirring and washing, then performing solid-liquid separation to obtain a solid wet product; the washing solvent includes ethyl acetate, methyl tert-butyl ether, or isopropyl ether; S3, drying the solid wet product to obtain purified esomeprazole sodium. This purification method is not only simple in process and has a high product yield, but also does not introduce new impurities, and the product has high optical and chemical purity.

This invention discloses a gelling material for treating gastric diseases and its preparation method, belonging to the field of pharmaceutical preparation technology. The gelling material is composed of 8-10g of Codonopsis pilosula extract, 6-10g of Bletilla striata extract, 6-8g of Dioscorea opposita extract, 2-4g of Citrus reticulata peel extract, 2-3g of gelatin, 2-4g of xylitol, 0.1-0.2g of citric acid, and 60.8-73.9g of purified water. As a carrier matrix, the gelling material of this invention exhibits good compatibility with commonly used antacids (such as calcium carbonate), PPIs (such as omeprazole), antibiotics (such as amoxicillin and clarithromycin), and traditional Chinese medicine extracts. During preparation, the above-mentioned active pharmaceutical ingredients (APIs) can be uniformly dispersed in the gel matrix, achieving integrated synergistic treatment of "mucosal protection + acid suppression / bactericidal action" without compromising their chemical stability or causing burst release problems, providing an ideal platform for developing compound gastric disease preparations.

Omeprazole is used as a widely applied proton pump inhibitor and is mainly used for treating various diseases caused by hyperacidity, such as gastric ulcer, duodenal ulcer, reflux esophagitis and the like. The invention relates to a novel application of a commercially available medicine omeprazole, namely the omeprazole has remarkable anti-aging activity. The research on model organism caenorhabditis elegans finds that omeprazole can significantly prolong the life of nematodes. Specifically, when the nematodes are cultured in culture media containing 1.6 mg / mL omeprazole and 3.2 mg / mL omeprazole, the service lives of the nematodes are prolonged by 47.80% and 61.51% respectively, and the effect is extremely rare in current drug research.

Omeprazole, as a widely used proton pump inhibitor, is mainly used for the treatment of various diseases caused by excessive gastric acid, such as gastric ulcer, duodenal ulcer and reflux esophagitis. The present application relates to a new use of a commercially available drug omeprazole, i.e. it has significant anti-aging activity. The present application found that omeprazole can significantly prolong the life of nematodes through research using model organisms Caenorhabditis elegans. Specifically, when the nematodes are cultured in a medium containing 1.6 mg / mL and 3.2 mg / mL omeprazole, their life is prolonged by 47.80% and 61.51% respectively, which is extremely rare in current drug research.

The application provides a compound omeprazole dry suspension and a preparation method thereof, and relates to the technical field of pharmaceutical preparations.The compound omeprazole dry suspension comprises the following raw materials: omeprazole, sodium bicarbonate, magnesium silico-aluminate, hard stearic acid modified hydrotalcite, low acyl gellan gum, hydroxypropyl methyl cellulose and trehalose.The application provides a compound omeprazole dry suspension and a preparation method thereof, and the compound omeprazole dry suspension with specific particle size is prepared through specific proportioning of auxiliary materials and a specific preparation process, and the stability and solubility are significantly improved.

An omeprazole delayed release tablet comprises a core and an enteric coating over the core. The core consists essentially of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate. The enteric coating over the core consists essentially of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, and less than 500 ppm of residual ammonium hydroxide.

The invention discloses an omeprazole nano-liposome and a preparation method thereof. The omeprazole nano-liposome is prepared in a film hydration method active packaging mode, targeted peptide modification is carried out, the generated modified omeprazole nano-liposome can successfully penetrate through a blood brain barrier, and sepsis related encephalopathy is effectively treated.

The invention relates to an escomeprazole enteric capsule as well as a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. The enteric capsule comprises an escomeprazole magnesium enteric pellet, the enteric pellet sequentially comprises a blank pellet core, an upper drug layer, an isolation layer and an enteric layer from inside to outside, the upper drug layer comprises escomeprazole and tris (hydroxymethyl) aminomethane, and the weight ratio of escomeprazole to tris (hydroxymethyl) aminomethane is 1: (0.01-0.03).

The application belongs to the technical field of coating materials, and particularly relates to a biodegradable medicinal casing based on a natural polysaccharide compound and a preparation method thereof. The biodegradable medicinal casing based on the natural polysaccharide compound comprises the following components in parts by weight: the enteric coating comprises the following components in parts by weight: 1-5 parts of pullulan, 20-25 parts of an enteric material, 6-10 parts of seaweed extract, 0.2-0.5 parts of a plasticizer, 5-9 parts of an anti-sticking agent, 0.20-0.25 parts of a pH regulator and 40-45 parts of water. The medicinal casing prepared in the application has high dissolution rate, strong stability and fast release speed when omeprazole is coated.

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

The application discloses a kind of micro-pellet type omeprazole enteric-coated capsules and preparation method thereof, including drug-containing pills, isolation layer and enteric layer, wherein the drug-containing pills comprise omeprazole, carboxymethyl chitosan, low-substituted hydroxypropyl cellulose, binder, filler and stabilizer;The mass ratio of omeprazole, carboxymethyl chitosan and low-substituted hydroxypropyl cellulose is 1:0.2-0.4:0.05-0.25;The micro-pellet type omeprazole enteric-coated capsule of the application does not contain organic solvent and surfactant, and the auxiliary material is simple, the micro-pellet particle size is uniform, the roundness is good, the surface finish is good, not easy to break, and the drug release effect is stable.

The invention provides an escomeprazole magnesium capsule preparation which is composed of a normal-release pellet and a sustained-release pellet, compared with a reference preparation 'NEXIUM', the escomeprazole magnesium capsule preparation has the effect taking speed close to that of the reference preparation and can maintain the effect taking time of 1-2 days, the drug administration frequency can be reduced, and the bioavailability of the escomeprazole magnesium capsule preparation is improved. The selectivity is increased for some patients who cannot take medicine every day, cannot be administrated in time or are inconvenient to take medicine for multiple times every day.

A method of treating patients who are positive for Helicobacter pylori infection comprises determining that a first patient who is positive for Helicobacter pylori infection has a body mass index corresponding to normal weight or overweight; determining that a second patient who is positive for Helicobacter pylori infection has a body mass index corresponding to obese or extremely obese; and administering to both the first patient and the second patient, for 14 days, a rifabutin-based triple therapy consisting essentially of rifabutin, amoxicillin and omeprazole or an equivalent amount of a pharmaceutically acceptable salt thereof, wherein, after treatment is complete, there is no substantial difference in the efficacy of the treatment when the treatment is administered to the first patient or the second patient.